biostudies-literatureUnknown67Maghbooli Z<h4>Background</h4>This study aimed to consider the main risk factors related to adverse clinical outcomes in MS patients with COVID-19.<h4>Methods</h4>Using the electronic health records systems, this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to August 2021. The severities of COVID-19 outcomes were admitted to ICU, hospitalization days, and in-hospital mortality.<h4>Results</h4>A total of 1634 hospitalized MS patients with a definite diagnosis of COVID-19 based on PCR were recorded in the electronic health systems. MS patients had a 7% increased risk for longer hospitalization, a 3% increased risk for the need to the ICU, and no increased risk of mortality compared with the general population. MS patients who were taking immunosuppressive (IS)-disease modifying therapies (DMT) had longer hospitalization (adjusted OR=2.06, 95%CI: 1.48, 2.86) and higher mortality risk (adjusted OR=2.05, 95%CI: 1.52, 6.29) compared to patients were under the immunomodulatory (IM)-DMT. There was not any significant association between the types of DMT and ICU (12.2% vs. 12.7%). Besides, MS patients who were vaccinated against COVID-19 before admission had shorter hospitalization (adjusted OR=0.40, 95% CI: 0.18, 0.92).<h4>Conclusions</h4>The current data suggest that MS healthcare providers should consider specific risks of severe COVID-19 infection before starting IS-DMT.Multiple sclerosis and related disorders104067https://www.ebi.ac.uk/biostudies/studies/S-EPMC9306262biostudies-literatureAssociation between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection.PMC9306262Fattahi MRHosseinpour HVarzandi TSahraian MAAghababaei YHamtaeigashi SMaghbooli ZMohammad-Nabi SfalseAssociation between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection.<h4>Background</h4>This study aimed to consider the main risk factors related to adverse clinical outcomes in MS patients with COVID-19.<h4>Methods</h4>Using the electronic health records systems, this is a cross-sectional study of two years of hospital admissions in terms of COVID-19 in Iran from March 2019 to August 2021. The severities of COVID-19 outcomes were admitted to ICU, hospitalization days, and in-hospital mortality.<h4>Results</h4>A total of 1634 hospitalized MS patients with a definite diagnosis of COVID-19 based on PCR were recorded in the electronic health systems. MS patients had a 7% increased risk for longer hospitalization, a 3% increased risk for the need to the ICU, and no increased risk of mortality compared with the general population. MS patients who were taking immunosuppressive (IS)-disease modifying therapies (DMT) had longer hospitalization (adjusted OR=2.06, 95%CI: 1.48, 2.86) and higher mortality risk (adjusted OR=2.05, 95%CI: 1.52, 6.29) compared to patients were under the immunomodulatory (IM)-DMT. There was not any significant association between the types of DMT and ICU (12.2% vs. 12.7%). Besides, MS patients who were vaccinated against COVID-19 before admission had shorter hospitalization (adjusted OR=0.40, 95% CI: 0.18, 0.92).<h4>Conclusions</h4>The current data suggest that MS healthcare providers should consider specific risks of severe COVID-19 infection before starting IS-DMT.2022-01-01T00:00:00Z2022 Nov2025-04-04T03:06:13.369Z2025-04-04T03:06:13.369ZS-EPMC93062623593375510.1016/j.msard.2022.104067